Literature DB >> 23756453

Does goal-directed fluid therapy affect postoperative orthostatic intolerance?: A randomized trial.

Morten Bundgaard-Nielsen1, Øivind Jans, Rasmus G Müller, André Korshin, Birgitte Ruhnau, Peter Bie, Niels H Secher, Henrik Kehlet.   

Abstract

BACKGROUND: Early mobilization is important for postoperative recovery but is limited by orthostatic intolerance (OI) with a prevalence of 50% 6 h after major surgery. The pathophysiology of postoperative OI is assumed to include hypovolemia besides dysregulation of vasomotor tone. Stroke volume-guided fluid therapy, so-called goal-directed therapy (GDT), corrects functional hypovolemia, and the authors hypothesized that GDT reduces the prevalence of OI after major surgery and assessed this in a prospective, double-blinded trial.
METHODS: Forty-two patients scheduled for open radical prostatectomy were randomized into standard fluid therapy (control group) or GDT groups. Both groups received a fixed-volume crystalloid regimen supplemented with 1:1 replacement of blood loss with colloid, and in addition, the GDT group received colloid to obtain a maximal stroke volume (esophageal Doppler). The primary outcome was the prevalence of OI assessed with a standardized mobilization protocol before and 6 h after surgery. Hemodynamic and hormonal orthostatic responses were evaluated.
RESULTS: Twelve (57%) versus 15 (71%) patients in the control and GDT groups (P = 0.33), respectively, demonstrated OI after surgery, group difference 14% (CI, -18 to 45%). Patients in the GDT group received more colloid during surgery (1,758 vs. 1,057 ml; P = 0.001) and reached a higher stroke volume (102 vs. 89 ml; P = 0.04). OI patients had an increased length of hospital stay (3 vs. 2 days; P = 0.02) and impaired hemodynamic and norepinephrine responses on mobilization.
CONCLUSION: GDT did not reduce the prevalence of OI, and patients with OI demonstrated impaired cardiovascular and hormonal responses to mobilization.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23756453     DOI: 10.1097/ALN.0b013e31829ce4ea

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  11 in total

1.  Association of conflicts of interest with the results and conclusions of goal-directed hemodynamic therapy research: a systematic review with meta-analysis.

Authors:  Lina Zhang; Feng Dai; Alexandria Brackett; Yuhang Ai; Lingzhong Meng
Journal:  Intensive Care Med       Date:  2018-08-13       Impact factor: 17.440

2.  Decreased heart rate variability responses during early postoperative mobilization--an observational study.

Authors:  Øivind Jans; Louise Brinth; Henrik Kehlet; Jesper Mehlsen
Journal:  BMC Anesthesiol       Date:  2015-08-22       Impact factor: 2.217

Review 3.  Intravascular volume therapy in adults: Guidelines from the Association of the Scientific Medical Societies in Germany.

Authors:  Gernot Marx; Achim W Schindler; Christoph Mosch; Joerg Albers; Michael Bauer; Irmela Gnass; Carsten Hobohm; Uwe Janssens; Stefan Kluge; Peter Kranke; Tobias Maurer; Waltraut Merz; Edmund Neugebauer; Michael Quintel; Norbert Senninger; Hans-Joachim Trampisch; Christian Waydhas; Rene Wildenauer; Kai Zacharowski; Michaela Eikermann
Journal:  Eur J Anaesthesiol       Date:  2016-07       Impact factor: 4.330

Review 4.  Enhanced Recovery After Surgery (ERAS) for gastrointestinal surgery, part 2: consensus statement for anaesthesia practice.

Authors:  A Feldheiser; O Aziz; G Baldini; B P B W Cox; K C H Fearon; L S Feldman; T J Gan; R H Kennedy; O Ljungqvist; D N Lobo; T Miller; F F Radtke; T Ruiz Garces; T Schricker; M J Scott; J K Thacker; L M Ytrebø; F Carli
Journal:  Acta Anaesthesiol Scand       Date:  2015-10-30       Impact factor: 2.105

Review 5.  Effect of perioperative goal-directed hemodynamic therapy on postoperative recovery following major abdominal surgery-a systematic review and meta-analysis of randomized controlled trials.

Authors:  Yanxia Sun; Fang Chai; Chuxiong Pan; Jamie Lee Romeiser; Tong J Gan
Journal:  Crit Care       Date:  2017-06-12       Impact factor: 9.097

6.  Comparison of volume and hemodynamic effects of crystalloid, hydroxyethyl starch, and albumin in patients undergoing major abdominal surgery: a prospective observational study.

Authors:  Daisuke Toyoda; Yuichi Maki; Yasumasa Sakamoto; Junki Kinoshita; Risa Abe; Yoshifumi Kotake
Journal:  BMC Anesthesiol       Date:  2020-06-03       Impact factor: 2.217

7.  Goal-directed haemodynamic therapy during general anaesthesia for noncardiac surgery: a systematic review and meta-analysis.

Authors:  Marie K Jessen; Mikael F Vallentin; Mathias J Holmberg; Maria Bolther; Frederik B Hansen; Johanne M Holst; Andreas Magnussen; Niklas S Hansen; Cecilie M Johannsen; Johannes Enevoldsen; Thomas H Jensen; Lara L Roessler; Peter C Lind; Maibritt P Klitholm; Mark A Eggertsen; Philip Caap; Caroline Boye; Karol M Dabrowski; Lasse Vormfenne; Maria Høybye; Jeppe Henriksen; Carl M Karlsson; Ida R Balleby; Marie S Rasmussen; Kim Pælestik; Asger Granfeldt; Lars W Andersen
Journal:  Br J Anaesth       Date:  2021-12-13       Impact factor: 11.719

8.  Perioperative restrictive versus goal-directed fluid therapy for adults undergoing major non-cardiac surgery.

Authors:  Anna Wrzosek; Joanna Jakowicka-Wordliczek; Renata Zajaczkowska; Wojciech T Serednicki; Milosz Jankowski; Malgorzata M Bala; Mateusz J Swierz; Maciej Polak; Jerzy Wordliczek
Journal:  Cochrane Database Syst Rev       Date:  2019-12-12

9.  Intraoperative Goal-directed Fluid Therapy in Elective Major Abdominal Surgery: A Meta-analysis of Randomized Controlled Trials.

Authors:  Katie E Rollins; Dileep N Lobo
Journal:  Ann Surg       Date:  2016-03       Impact factor: 12.969

10.  Lack of impact of nil-per-os (NPO) time on goal-directed fluid delivery in first case versus afternoon case starts: a retrospective cohort study.

Authors:  R Ryan Field; Tuan Mai; Samouel Hanna; Brian Harrington; Michael-David Calderon; Joseph Rinehart
Journal:  BMC Anesthesiol       Date:  2019-10-27       Impact factor: 2.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.